Prot# WA20499 / ACT4071g: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus

Project: Research project

Project Details

StatusFinished
Effective start/end date1/11/08 → 1/11/11

Funding

  • Quintiles, Inc. (WA20499 / ACT4071g // WA20499 / ACT4071g)
  • Genentech, Inc (WA20499 / ACT4071g // WA20499 / ACT4071g)